E3 ubiquitin ligase adapter, Cancer/testis antigen, MAGE family protein
01
Overview
Melanoma-associated antigen F1 (MAGEF1) is a member of the MAGE protein family, defined by the conserved MAGE homology domain. MAGEF1 acts as a substrate adapter and enhancer for E3 ubiquitin ligase complexes, particularly promoting proteasomal degradation of key regulatory proteins such as MMS19, with downstream impacts on DNA repair and genome stability. Aberrant expression of MAGEF1 is associated with several cancers, most notably melanoma, making it a key cancer/testis antigen and a candidate target for immunotherapy and novel anticancer agents. MAGEF1 is evolutionarily conserved, and its biological roles are being elucidated in the context of ubiquitin-mediated proteostasis and DNA repair regulation.
Other names
MAGE family member F1Melanoma-associated antigen F1MAGEF1MAGE-F1MAGE-F1 antigenMelanoma antigen family F, 1Melanoma antigen family F1
02
Mechanism of action
When targeted, mechanisms would likely involve: Small molecules or biological agents blocking substrate binding or disrupting interaction with E3 ligases, thereby altering ubiquitination and proteasomal degradation of specific targets. Immunotherapy approaches aimed at eliciting immune responses against MAGEF1-expressing tumor cells.
03
Biological functions
Enhancing E3 ubiquitin ligase activity (in concert with RING-type E3 ligases, e.g., NSE1)Mediating proteasomal degradation of specific substrates (e.g., MMS19)Regulation of DNA repair processes, notably by inhibiting homologous recombination-mediated double-strand break repairNegative regulation of genome integrityProtein–protein interactions via substrate recruitment/adaptation
04
Disease associations
Cancer (notably melanoma and other tumors where cancer/testis antigens are expressed)Potentially involved in DNA repair disorders via impact on genome stability
05
Safety considerations
MAGE family antigens are normally restricted to germ cells and undetectable in adult somatic tissues, but aberrant expression in somatic cells (such as in tumors) is a hallmark of cancer/testis antigensTherapeutic targeting of MAGEF1 may carry risks of off-target effects on germ cells, but this risk is theoretically lower because outside cancer/testis contexts, expression is limited
06
Interacting drugs
There are currently no well-established drugs that directly target MAGEF1 in clinical use; MAGE family proteins are being explored as immunotherapy targets and as candidates for development of small-molecule inhibitors
07
Biomarkers
Expression of MAGEF1 (and other MAGE family members) is used as a biomarker for the presence of certain cancers, especially melanoma, and for the selection of patients for immunotherapies targeting cancer/testis antigens
Beyond the preview
Go deeper on Melanoma-associated antigen F1 (MAGEF1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoma-associated antigen F1 (MAGEF1).